SCHEMBL16570855

SCHEMBL16570855

O=S(=O)(c1ccc(Nc2ncc3ccn(Cc4cccnc4)c3n2)cc1)C(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 1/20 0.57
▸ JAK3 P52333 3/20 0.53
▸ CDK1 P06493 3/20 0.53
▸ JAK2 O60674 3/20 0.53
▸ CDK2 P24941 2/20 0.53
▸ KDR P35968 2/20 0.53
▸ AURKA O14965 1/20 0.53
▸ DCLK1 O15075 1/20 0.53
▸ PDPK1 O15530 1/20 0.53
▸ ROCK2 O75116 1/20 0.53
▸ PRKD3 O94806 1/20 0.53
▸ MAP4K4 O95819 1/20 0.53
▸ EGFR P00533 1/20 0.53
▸ NTRK1 P04629 1/20 0.53
▸ PRKCG P05129 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ FYN P06241 1/20 0.53
▸ LYN P07948 1/20 0.53
▸ RET P07949 1/20 0.53
▸ IGF1R P08069 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570521 0.83 PTK2 (0.41) PTK2JAK3CDK1JAK2CDK2
SCHEMBL16580900 0.80 STAT6 (0.48) PTK2JAK3CDK1JAK2CDK2
SCHEMBL12529138 0.73 PTK2 (1.00) PTK2JAK3JAK2KDRAURKA
SCHEMBL16570474 0.72 BCL6 (0.59) PTK2JAK3CDK1JAK2CDK2
SCHEMBL16570339 0.72 PTK2 (0.55) PTK2JAK3CDK1JAK2CDK2
SCHEMBL31299861 0.71 PTGS1 (0.52) PTK2JAK3CDK1JAK2CDK2
SCHEMBL342369 0.71 CDK1 (0.58) PTK2JAK3CDK1JAK2CDK2
SCHEMBL12528777 0.69 PTK2 (0.66) PTK2JAK3CDK1JAK2CDK2
SCHEMBL12529157 0.69 PTK2 (0.66) PTK2JAK3CDK1JAK2CDK2
SCHEMBL16570231 0.67 PTK2 (0.54) PTK2JAK3JAK2SRPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN PTK2 2/4885JAK3 124/4885CDK1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback